Challenging Paradigms in AMD: Gregory S. Hageman, PhD

Video

The executive director of the Steele Center for Translational Medicine at the Moran Eye Center discussed his team’s research in the role of HTRA1.

“There are a number of programs out there that are directing approaches to decrease [HTRA1] levels with antibodies... So, I've gotten calls from those folks who are thinking, ‘oh man, what have we done’, but more of the calls are from the pharma companies that say, ‘oh, all these other big companies are [downregulating]. We'd like to investigate upregulating now.”

HTRA1 had previously been thought to contribute to the development of age-related macular degeneration (AMD), with multiple studies currently ongoing investigating the downregulation of HTRA1 as a therapeutic target. However, recent research from the John A. Moran Eye Center at the University of Utah has elucidated the true role of HTRA1 and another important gene in AMD, ARMS2.

GeneTherapyLive spoke with Brandi. L Williams, PhD, research director, and Gregory S. Hageman, PhD, executive director, Steele Center for Translational Medicine, both from the John A. Moran Eye Center, to learn more about the implications of their findings that HTRA1 has a protective effect on AMD as opposed to contributing to an increased risk of AMD.

Williams and Hageman detail the culmination of 15 years of research in the paper they recently published in PNAS. They also discussed the trials investigating HTRA1 as a therapeutic target.

REFERENCE
Williams BL, Seager NA, Gardiner JD, et al. Chromosome 10q26–driven age-related macular degeneration is associated with reduced levels of HTRA1 in human retinal pigment epithelium. PNAS. 2021;118(30) e2103617118. doi:10.1073/pnas.2103617118
Recent Videos
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Jamie Jacobs, PhD, the program director of the center for psychiatric oncology & behavioral sciences at Mass General Cancer Center
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Sarah Hein, PhD, the chief executive officer and cofounder of March Biosciences
Brian Kim, MBA, the chief executive officer of Mission Bio
Peter Cook, PhD, a senior research scientist at Seattle Children’s Research Institute
Nicholas Giovannone, PhD, a senior principal scientist at Regeneron
Related Content
© 2025 MJH Life Sciences

All rights reserved.